Neoleukin Therapeutics, Inc. (NLTX)
Stock Price:
$11.99 USD
0.39 (3.36%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $12.25 +0.26 (2.17%) Aug 12, 4:29 PM
Key Info
| Market Cap |
500.55M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-75.88M |
| Shares Out |
38.49M |
| EPS (ttm) |
-2.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$11.99 |
| Previous Close |
$11.60 |
| Change ($) |
0.39 |
| Change (%) |
3.36% |
| Day's Open |
11.65 |
| Day's Range |
11.48 - 12.03 |
| Day's Volume |
240,464 |
| 52-Week Range |
2.53 - 18.13 |
More Stats
| Market Cap |
500.55M |
| Enterprise Value |
372.06M |
| Earnings Date (est) |
Aug 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.49M |
| Float |
20.34M |
| EPS (basic) |
-2.5 |
| EPS (diluted) |
-2.74 |
| FCF / Share |
-0.41 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.36M |
| Short Ratio |
6.21 |
| Short % of Float |
9.84% |
| Beta |
-4.54 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.00 |
| Revenue |
n/a |
| Operating Income |
-77.37M |
| Net Income |
-75.88M |
| Free Cash Flow |
-20.06M |
| Net Cash |
128.49M |
| Net Cash / Share |
3.08 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-17.04% |
| ROE |
-72.73% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$22.00*
(83.49% upside)
Low
20.0
Current: $11.99
High
28.0
Target: 22.00
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | 25.00 | - | - | - | - | - | - |
| Gross Profit | - | 25.00 | - | - | - | - | - | - |
| Operating Income | -70.96 | -32.62 | -51.12 | -37.65 | -21.34 | -22.38 | -9.38 | -7.68 |
| Net Income | -69.44 | -31.59 | -50.18 | -37.00 | -21.86 | -24.03 | -8.73 | -7.71 |
| Shares Outstanding | 27.03 | 23.52 | 23.45 | 18.89 | 12.64 | 8.67 | 0.30 | 0.30 |
| Earnings Per Share | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -49.52 | -40.23 |
| Operating Cash Flow | -15.39 | -31.58 | -44.72 | -30.23 | -20.27 | -17.49 | -7.82 | -7.23 |
| Capital Expenditures | -0.88 | -0.05 | -0.49 | -0.71 | -0.03 | -0.09 | 0.18 | -0.01 |
| Free Cash Flow | -16.27 | -31.63 | -45.21 | -30.94 | -20.29 | -17.57 | -7.64 | -7.24 |
| Cash & Equivalents | 143 | 76.93 | 108 | 103 | 74.48 | 39.10 | 13.83 | 2.00 |
| Total Debt | 1.21 | 0.02 | - | - | - | - | 2.29 | - |
| Net Cash / Debt | 142 | 76.91 | 108 | 103 | 74.48 | 39.10 | 11.54 | 2.00 |
| Assets | 147 | 77.62 | 110 | 154 | 113 | 41.42 | 15.65 | 2.34 |
| Liabilities | 5.34 | 4.95 | 11.44 | 9.72 | 4.92 | 5.28 | 7.48 | 1.47 |
| Book Value | 142 | 72.67 | 98.89 | 145 | 108 | 36.15 | -65.69 | -51.10 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Neoleukin Therapeutics, Inc. |
| Country |
United States |
| Employees |
45 |
| CEO |
Jonathan G. Drachman |
Stock Information
| Ticker Symbol |
NLTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NLTX |
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.